Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study
New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data. read more.....»»
Stealth BioTherapeutics" stock falls on trial failure
Shares of Stealth BioTherapeutics tumbled 63% after it said a late-stage trial for its investigational treatment of primary mitochondrial myopathy, a muscular disease caused by genetic mutations, failed to meet the study's primary endpoint. .....»»
Cassava stock falls on failed Alzheimer"s study
Shares of Cassava Sciences Inc. tumbled 73.2% in trading on Friday after the company said its investigational Alzheimer's disease treatment failed a mid-.....»»
Applied Genetic Slumps Despite Encouraging Data For Gene Therapy To Treat Rare Inherited Visual Disorder
Shares of Applied Genetic Technologies Corp (NASDAQ: AGTC) are tumbling Thursday despite the company reporting encouraging results from an Phase 1/2 study. 0 read more.....»»
First Week of January 2020 Options Trading For Ultragenyx Pharmaceutical (RARE)
Stock Options Channel.....»»
Takeda shares drop after Shire rejects $63 billion offer
TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd shares fell on Friday after rare disease drug maker Shire Plc rejected its $63 billion cash-and-stock acquisition offer......»»
Ultragenyx stock halted on late-stage trial failure
Ultragenyx Pharmaceutical Inc. [s:RARE] shares were halted in Friday premarket trade on .....»»
Ultragenyx stock drops 14% on late-stage trial failure
Ultragenyx Pharmaceutical Inc. [s:RARE] shares dropped 14% in Friday premarket trade on .....»»
Ultragenyx stock up 2.9% after safety and efficacy trial reaffirms Phase 2 data
Shares of Ultragenyx Pharmaceutical Inc. rose 2.9% in premarket trade Tuesday after the company announced positive results from a safety and efficacy study looking at a treatment for patients with lo.....»»
EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
Adial Pharmaceuticals' genetic diagnostic patent, expanding treatment for alcohol and drug dependencies. CEO highlights the significance. read more.....»»
Myovant"s stock falls after FDA puts partial clinical hold on trial for contraceptive candidate
Shares of Myovant Sciences Ltd. were down 5.7% in premarket trading on Wednesday after the company told investors that the Food and Drug Administration had placed a partial clinical hold on a study assessing an experimental birth c.....»»
Ultragenyx announces longer-term data from Glycogen Storage Disease study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
ChemoCentryx"s stock dives after critique from the FDA about experimental treatment for rare autoimmune disease
Shares of ChemoCentryx Inc. plunged 44.8% in trading on Tuesday after the Food and Drug Administration questioned the rat.....»»
J&J to resume COVID-19 vaccine shipments to EU, with a warning "very rare" adverse events
Shares of Johnson & Johnson jumped 2.6% toward a 12-we.....»»
Ultragenyx Pharmaceutical Inc (RARE) EVP and Chief Medical Officer Camille L Bedrosian Sold ...
Related Stocks: RARE,.....»»
Moleculin Biotech Stock Is Trading Higher After WP1066 Scores Rare Pediatric Disease Tag For Type Of Brain Tumor
read more.....»»
Ionis shares tumble 19% after Roche halts Phase 3 study for rare-disease drug
Shares of Ionis Pharmaceuticals Inc. were down 19.6% in premarket trading on Tuesday, the day after the company said Roche Holding AG decided to discontinue.....»»
Ionis shares tumble19% after Roche halts Phase 3 study for rare-disease drug
Shares of Ionis Pharmaceuticals Inc. were down 19.6% in premarket trading on Tuesday, the day after the company said Roche Holding AG decided to discontinue.....»»
Tackling deadly newborn disease, BridgeBio affiliate wins FDA drug approval
The BridgeBio model is designed to move drugs tackling rare diseases with a well-defined genetic basis quickly and efficiently to approval......»»
BridgeBio Pharma Gets First FDA-Approval For Rare Genetic Metabolic Disorder
BridgeBio Pharma Inc (NASDAQ: BBIO) and affiliate Origin Biosciences Inc have received the read more.....»»